The interaction between the Fc domain of IgG antibodies and Fc receptors has an important role in antibody-dependent cellmediated cytotoxicity (ADCC) 1-3 , complement-dependent cytotoxicity (CDC) 4 , anti-inflammatory activity [5] [6] [7] , pharmacokinetic half-life 8, 9 , and immunogenicity 10 . These interactions are regulated by N-glycosylation of the IgG Fc domains [11] [12] [13] [14] . Various glycoengineering technologies have emerged, aiming at enhancing the efficacy of therapeutic antibodies through N-glycosylation 10 . In addition to the approaches to in vivo N-glycoengineering through glycosyltransferase knockout/knock-in expression systems 2, 15, 16 and in vitro treatment of antibodies with glycosyltransferases 17,18 , endoglycosidase-catalyzed N-glycosylation remodeling has become a powerful tool for the synthesis of homogeneous N-glycoproteins [19] [20] [21] [22] [23] [24] [25] [26] [27] . This chemoenzymatic method exploits the hydrolytic activity of wild-type (WT) endoglycosidases to cleave heterogeneous N-glycans and leave the innermost GlcNAc motifs on the glycoproteins. Next, endoglycosidase mutants 28 , also called glycosynthases-which lack hydrolytic activity but possess transglycosylation activity through the use of a homogeneous synthetic N-glycan oxazoline as the activated substrate-are used to assemble this intact N-glycan substrate on the GlcNAc-bearing glycoprotein generated by the aforementioned deglycosylation by the WT enzyme to accomplish the glycoengineering. Endo-β-Nacetylglucosaminidase from Streptococcus pyogenes (Endo-S), as one of these endoglycosidases, specifically recognizes the IgG Fc domain and has been used for efficient glyco-remodeling of therapeutic antibodies [21] [22] [23] [24] [25] [26] . The glycan substrate specificity of Endo-S covers a wide range of natural and modified N-glycan structures.
from different species (e.g., human, mouse, rabbit, goat) with various natural and non-natural N-glycans. In vitro glycoengineering circumvents the limitations of the in vivo glycoengineering technology, which requires expression optimization for each IgG and particular N-glycan in an engineered expression system by knockout/knock-in of key glycosyltransferases 2, 10, 34 . Other in vitro glycoengineering technologies using glycosyltransferases have limited substrate specificity, as the transferases recognize monosaccharide moieties on the sugar structure within a limited tolerance [30] [31] [32] . By contrast, Endo-S has a broad substrate scope and allows for a wider diversity of modifications on the nonreducing end. Moreover, it remains very challenging to prepare homogeneous glycoforms using in vivo technologies or the glycosyltransferase-catalyzed in vitro technology, because natural IgGs may carry highly heterogeneous N-glycans and some of them cannot be used as a substrate for certain glycosyltransferases. The current method removes all external N-glycans and remodels these glycans with well-defined synthetic substrates.
The ability to engineer antibody N-glycans in a site-specific manner enables specific functionalization on the Fc glycosite Asn297, which is highly conserved in various mammalian IgGs, and allows chemical modifications of this particular site. Compared with other site-specific conjugation strategies such as ThioMab technology 35 , unnatural amino acid embedding 36 , and the glycosyltransferase approach 30, 31 , this method describes a simple procedure with lower technical requirements. Some key materials used in this method are already commercially available, including the endoglycosidases (Endo-M (endo-β-N-acetylglucosaminidase from Mucor hiemalis) and Endo-S), α-l-fucosidase, egg-yolk sialylglycopeptide (SGP), toxins, and linkers. More importantly, this method works efficiently in almost quantitative yields based on liquid chromatography-mass spectrometry (LC-MS) analysis and provides highly homogeneous end products.
Low efficiency in IgG defucosylation, a critical step in enhancing the ADCC of therapeutic antibodies, was a major limitation of the original version of this method, as it required a lengthy procedure (3 weeks). Recently, two better fucosidases were reported with markedly enhanced activity, allowing the digestion time to be shortened to 1 d 23, 25 . We followed the literature 25 and updated our current protocol to incorporate one of these. As compared with that for monosugar substrates in the glycosyltransferase approaches, the higher cost of total synthesis of complex N-glycan substrates in this method was another concern for its practical application in industry. To address this issue, we had previously optimized the extraction procedure for precursor SGP from egg yolk to the gram scale 37 ; this optimized procedure can be used for semisynthesis of the substrates and to develop scaled-up procedures. Another challenge was that multiple purification steps are required for the antibody after deglycosylation, transglycosylation, and conjugation. We have applied the Endo-S enzymes to a magnetic nanoparticle solid support in order to simplify the procedure (data not shown).
Since the original method was published, we and other scientists have made substantial improvements, including the development of one-pot chemoenzymatic procedures 26 , use of new endoglycosidases 25 and improved fucosidases 23, 25 , identification of various N-glycan substrates 23, 26 , the introduction of different types of modification chemistry 24, 37, 38 , and an optimized procedure for N-glycan extraction 37 , to broaden the adaptation of this method. We report here the updated protocol describing all required steps of this approach.
Applications
This protocol can be used for the synthesis of homogeneous glycoengineered therapeutic antibodies and gsADCs. Glycoengineered IgGs with optimized glycoforms attracted great interest from researchers and exhibited enhanced ADCC and/or CDC efficacy, especially for cancer treatment 1, 4, 10 . ADCs exploit the high binding affinity of the antibody to a particular antigen to deliver the conjugated toxin to cancer cells. As compared with the random conjugation on Lys or Cys amino acids of traditional ADCs, gsADCs have obvious advantages, such as convenient quality control, more consistent efficacy, and simplified pharmacokinetic detection.
This protocol is also useful for site-specific labeling or modification of IgG antibodies. Antibody labeling is a basic technology used in antigen-binding affinity assays, immunofluorescence microscopy, western blotting, FACS analysis, ELISA, and so on. However, labeling antibodies at random sites may also modify the antigen-binding fragment (Fab) and alter the antigen-binding efficacy of antibodies. The current method allows for specific labeling on the Fc fragment and therefore minimizes its influence on the Fab domains. Other site-specific modifications of antibodies, such as PEGylation, protein cross-linking, and immunoliposome formation, could also be achieved using this protocol.
Overview of the procedures
The main procedures of Endo-S-catalyzed synthesis of glycoengineered IgG and gsADCs are summarized in Figure 1 . The procedures consist of the following key steps:
(i) Preparation of deglycosylated IgG (2) bearing disaccharide Fucα1,6GlcNAc (2a) or monosaccharide GlcNAc (2b) from commercial therapeutic IgG (1). This is done by removal of the heterogeneous N-glycans from the specific Fc glycosite Asn297 of the native IgGs using Endo-S or Endo-S treatment combined with further defucosylation by the α-l-fucosidase C (AlfC) from Lactobacillus casei. (ii) Semisynthesis of homogeneous N-glycopeptides (4a-f) as the N-glycan substrate precursors from an egg-yolk SGP (3). (iii) One-pot chemoenzymatic synthesis of glycoengineered IgGs (5a-e) by transglycosylating the synthetic N-glycopeptide substrates (4a-f) onto Fucα1,6GlcNAc-IgG (2a) or GlcNAc-IgG (2b), catalyzed by a mutation (D233Q) of the Endo-S enzyme. (iv) Site-specific conjugation of dibenzoazacyclooctyne (DBCO)-tagged small molecules (6a-d) to the azido-functionalized N-glycans of IgG (5a) via a copper-free 'click' reaction, yielding the gsADCs (7a-f).
The flowchart in Figure 2 provides an overview of the procedures. A simplified procedure for SGP extraction from egg yolks is provided in Box 1. Using SGP as the precursor, semisynthesis of nonnatural SGP analogs carrying azido or alkyne functional groups is shown in Steps 1-17. N-glycan oxazolines are activated substrates of endoglycosynthases (endoglycosidase mutants) used for chemoenzymatic transglycosylation. From SGP or its analogs, the oxazoline substrates can be prepared via a one-pot reaction combined with N-glycan removal from the glycopeptides with Endo-M from Mucor hiemalis 39 and successive oxazoline formation in aqueous solution 40 (Steps 18-45). The in situ N-glycan oxazolines derived from SGP or its analogs can also be used directly in one-pot chemoenzymatic glycoengineering in the presence of preprepared GlcNAc-bearing IgG (2a or 2b) and Endo-S D233Q (Steps 74-85). The same chemoenzymatic transglycosylation reactions using purified N-glycan oxazolines are shown in Steps 63-73. Preparation of GlcNAc-IgG from deglycosylation of native IgG by WT Endo-S and α-L-fucosidase AlfC is described in Steps 46-62. The cloning, expression, and purification of the enzymes Endo-M, α-l-fucosidase AlfC, Endo-S WT, and its mutant D233Q are performed as described in the literature 25, 26, 28 with modification as described in the Supplementary Results. Enzyme activity is critical to the deglycosylation and transglycosylation steps. We therefore describe the activity assays and unit definition for these enzymes in Box 2. DBCO-linked toxins (see Fig. 3 and Box 3 for their synthesis) are attached to the azido-tagged N-glycans of glycoengineered IgGs, via copper-free 'click' reaction, to yield the gsADCs (Steps 86-95). Through the combination of the glycosite-specific strategy and the random Lys conjugation, dual-payload ADC is achieved as described in Steps 96-108.
Experimental design
Before using this protocol for IgG glycoengineering, the availability of required materials and instruments must be confirmed. Follow Boxes 1-3 to prepare the key items for SGP synthesis, to test the activity of the required enzymes, and to prepare the small-molecule toxins for gsADCs. Analytical and preparative HPLC instruments are required for preparation of N-glycan substrates and toxins. LC-MS in a high mass range (2,000-5,000 Da) with deconvolution software for MS protein detection is very important for monitoring IgG glycoengineering and gsADC synthesis. In critical steps, efficient monitoring and characterization of the reactions and products is critical to good results. The synthesis of SGP analogs and DBCO-linked small molecules is carried out and measured by analytic HPLC at time intervals (see Supplementary Results, Products 4a-f), and their purification is subject to preparative HPLC. N-glycan oxazoline formation in the presence of 2-chloro-1,3-dimethylimidazolinium chloride (DMC) is monitored with high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) and 1 H NMR analysis (see Supplementary Results, products 22-26). This is to ensure a high conversion rate, which is particularly important for the sequential steps of chemoenzymatic transglycosylation using these in situ oxazolines via the one-pot strategy. SDS-PAGE and LC-MS are major tools for detection of IgG glycoengineering and gsADC conjugation (see Supplementary Results, products 5a-e and 7a-f). The band shift of IgG heavy chains after deglycosylation/glyco-remodeling on SDS-PAGE can roughly determine the efficiency of the enzymatic reaction. Moreover, LC-MS detection provides precise data on the intact IgG that can be used for monitoring the glycoengineering process (see examples in the Anticipated Results section).
When following this protocol, we suggest starting with a test scale of 100-200 µg of IgG, especially for precious antibody samples.
The enzymatic transglycosylation (Steps 63-85) is the limiting step in the PROCEDURE, as the reaction yield is greatly dependent on the quality of N-glycan oxazolines, the enzyme activity, and the buffer pH and concentration. Optimization of these steps might be required to attain good results (see the Troubleshooting section for details) before scaling up to the milligram or higher scale.
Box 1 | Extraction and purification of SGP • tIMInG 4 d
SGP as a homogeneous N-glycan precursor is extracted from chicken egg yolk by successive procedures of defatting with ether, extraction with aqueous acetone, SPE with active carbon, and isolation with G-25 gel-filtration chromatography. 1. Take 200 eggs (purchased from local market). Open each shell and carefully separate the egg yolk from the egg-white liquid. 2. Put all the egg yolks in a 5-liter beaker. Add 1 liter of water and stir the mixture at RT for 30 min. 3. Lyophilize the mixture until dryness to obtain ~1.5 kg of egg-yolk powder. This step takes ~1 d. 4. Weigh 1.2 kg of egg-yolk powder from step 3 in a 10-liter beaker. Add 4 liters of tert-butyl methyl ether to the powder and stir at RT for 1 h. Filter the solid through a Buchner funnel and discard the liquid. Mix the filter cake with an additional 4 liters of tert-butyl methyl ether and repeat the stirring and filtration. Repeat this with 1 liter of tert-butyl methyl ether three times. This step takes ~2-3 h. 5. Stir the filter cake from step 4 with 4 liters of 70% acetone solution in a 10-liter beaker at RT for 30 min, filter the solid, and discard the liquid. Mix the filter cake with an additional 4 liters of 70% acetone solution and repeat the stirring and filtration. This step takes ~2 h. 6. Stir the filter cake from step 5 with 4 liters of 40% acetone solution in a 10-liter beaker at RT for 1 h. Filter the solid and collect the filtrate. Mix the filter cake with an additional 4 liters of 40% acetone solution and repeat the stirring and filtration. Concentrate the combined filtrate to 1 liter using a Rotavapor. This step takes ~3-5 h.  crItIcal step Set the water bath temperature of the Rotavapor below 35 °C (also for step 9). High temperatures, especially in combination with a low pH, may cause partial removal of the terminal sialic acid from SGP. 7. Prepare a column (10 × 10 cm, see EQUIPMENT section) filled with a mixture of 100 g of active carbon and 100 g of celite, prewashed with 1 liter of water. Flow the concentrated solution from step 6 through the column three times. This step takes ~1-2 h.  crItIcal step Avoid using a lathy column. This will cause high pressure and takes a long time to wash and elute. 8. Wash the column successively with 2 liters of pure water, 2 liters of 5% acetonitrile, and 2 liters of 10% acetonitrile. Elute the column two times with 2 liters of 25% acetonitrile. This step takes ~2-4 h. 9. Concentrate the combined elution solution from step 8 to a 500-ml volume using a Rotavapor. Lyophilize the residue to obtain 1.5 g of the crude SGP as a pale-yellow powder. This step takes ~1 d. 10 . Dissolve the crude SGP from step 9 in 5 ml of water and centrifuge the solution at 3,200g at 4 °C for 30 min. 11. Take the supernatant from step 10 and load it onto a Sephadex G-25 column (2.6 × 80 cm). Elute the column with water. Collect the fractions containing SGP and lyophilize the combined fractions to obtain 0.5 g of SGP (purity >95%). This step takes ~1 d.  crItIcal step The crude SGP contains ~15% of a partial desialyl form with only one sialic acid on the nonreducing end of the SGP molecule. Gel-filtration with a G-25 column eluted with water or a 0.1 M acetic acid aqueous solution can separate the partial desialyl form from the pure SGP. However, if the crude SGP sample is overloaded or is in a large loading volume, the produced SGP may contain 5-15% of the mono desialyl form. In that case, repeated G-25 purification might be needed to obtain high-quality SGP. ? trouBlesHootInG 12. Monitor all the above processes with analytic HPLC. Also detect separation of SGP and its partial desialyl form with monosialic acid with HPAEC-PAD.  pause poInt SGP can be stored at −20 °C for 6 months or at −80 °C for 12 months. • 1-liter and 100-ml cylinders (Sinopharm Chemical Reagent) 1-liter, 500-ml, 250-ml, and 100-ml liquid storage bottles (Sinopharm Chemical Reagent) 50-ml and 15-ml Tubes (Jet Biofil, cat. nos. CFT011500, CFT011150) 10-ml, 5-ml, 2.0-ml, 1.5-ml, and 0.2-ml centrifuge tubes (Sanhe) Buchner funnel (assorted sizes; Sinopharm Chemical Reagent) Custom-ordered glass column (10 × 20 cm; Xiamei) for active carbon-celite mixture. Pack the mixed active carbon-celite (1:1) into the column until the column is half full (at the 10-cm mark). Custom-ordered glass column (2.6 × 100 cm; Xiamei) for Sephadex G-25 beads. Swell the G-25 beads in water and pack the mixture into the column until the column is 80% full (at the 80-cm mark This solution should be freshly prepared and kept away from light. 5, 10, and 25% Acetonitrile Mix 950 ml of water and 50 ml of acetonitrile to make 1 liter of 5% acetonitrile solution. Mix 900 ml of water and 100 ml of acetonitrile to make 1 liter of 10% acetonitrile solution. Mix 750 ml of water and 250 ml of acetonitrile to make 1 liter of 25% acetonitrile. These solutions should be freshly prepared. 5, 10, and 25% (vol/vol) Acetonitrile containing 1 mM NaOH Dissolve 400 mg of sodium hydroxide in 10 ml of water to make a 1.0 M NaOH solution. This solution can be stored at 4 °C for 2 weeks. Mix 94.9 ml of water, 5 ml of acetonitrile, and 100 µl of 1.0 M NaOH to make a 5% acetonitrile solution containing 1 mM NaOH. Mix 89.9 ml of water, 10 ml of acetonitrile, and 100 µl of 1.0 M NaOH to make a 10% acetonitrile solution containing 1 mM NaOH. Mix 74.9 ml of water, 25 ml of acetonitrile, and 100 µl of 1.0 M NaOH to make a 25% acetonitrile solution containing 1 mM NaOH. These acetonitrile solutions should be freshly prepared. Elute the column with an isocratic gradient of 5% acetonitrile (buffer B) and 95% water containing 0.1% formic acid (buffer A) for the first 10 min, a linear gradient of 5-95% acetonitrile for an additional 10 min, and an isocratic mobile phase of 95% acetonitrile for another 10 min at a flow rate of 0.2 ml/min. Perform the mass spectra measurement of antibodies under the extended mass range mode (high 20,000 m/z, 1 GHz) and collect the data in the mass range of 800-5,000. Key source parameters are as follows: drying nitrogen gas flow of 11 liters/min; nebulizer pressure of 60 psi; gas temperature of 350 °C; fragmenter voltage of 400 V; skimmer voltage of 65 V; and capillary voltage of 5,000 V. Deconvolute the multiple charged peaks of the antibody using the Agilent MassHunter Bioconfirm software (deconvolution for protein, Agilent Technology) with a deconvolution range of 100-200 kDa; set the other parameters to default values for the protein deconvolution. Calibrate the TOF over the range of 0-5,000 m/z using Agilent ESI calibration mix solution before analysis. The peak of MS 922 is the internal standard for calibration. HPAEC-PAD In our lab, the HPAEC spectra are performed on an ICS 5000 + system (Thermo Scientific) with a PA100 anion exchange column (4 × 250 mm) and a guard column (4 × 50 mm) at 30 °C. The mobile phases consist of a water phase (solvent A), a 1.0 M sodium acetate aqueous solution (solvent B), and a 0.2 M sodium hydroxide aqueous solution (solvent C). Using this system (or one very similar), elute the column with an isocratic mobile phase of 50/0/50 (solvent A/B/C) for the first 2 min and then a linear gradient of 50/0/50 to 35/15/50 (solvent A/B/C) for an additional 20 min at a flow rate of 1 ml/min. Sephadex G-25 gel-filtration Swell 100 g of G-25 beads in 400 ml of water and pack the mixture into a custom-ordered glass column (2.6 × 100 cm, Xiamei) until the column is 80% full (at the 80-cm mark). The G-25 column is eluted with 3 column volumes of water, 0.2% triethylamine aqueous solution, or other suitable solvents by gravity. The fractions are collected by an automatic fraction collector instrument (BS-100A). For SGP and analog detection, we take 0.5-µl samples from each fraction tube and test them on a TLC plate stained with 10% sulfate acid in ethanol after drying with a heat gun. The fractions containing SGP product will develop black spots on the TLC plate after staining. NMR NMR spectra were measured on a Varian Mercury Plus 400 or 500 instrument. 
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Herceptin solution
9| Stir within an ice bath for 4 h and monitor the reaction with HPLC (supplementary results).
10| Immediately purify the reaction mixture by gel-filtration with a G-25 column (see Box 1, step 10 for column information). Elute the column with water.
11|
Lyophilize the collected fractions to obtain a white powder (4a; yield 92%).  pause poInt The SGP analog 4a can be stored at −20 °C for 3 months or at −80 °C for 12 months.
semisynthesis of azido-amine-sGp (4b)
• tIMInG 5 h 12| Weigh 10 mg (3.65 µmol) of CHO-SGP (purified; from Step 5) in a 2.0-ml tube, and add 0.5 ml of cold 50 mM, pH 6.0 phosphate buffer and 0.5 ml of cold methanol (4 °C).
13| Add 3-azido-1-propanamine (10.8 µl, 109.5 µmol, 30 equiv.) and adjust the pH to 6.0 with acetic acid.
14|
Add NaCNBH 3 (4.6 mg, 73 µmol, 20 equiv.).  crItIcal step It is important to weigh and add NaCNBH 3 quickly, as it is labile in air. 19| Add 230 µl of 50 mM, pH 6.25 phosphate buffer. Adjust the pH to 6.25 with 0.1 N NaOH.  crItIcal step Compound 4a was purified from preparative HPLC with mobile phases containing 0.1% TFA; it is acidic because of remaining TFA after lyophilization. When dissolving it in a buffer, the pH of the mixture solution might be lower than the buffer pH and extra NaOH must be added to adjust the final pH to the expected value. 24| Weigh 43.6 mg (258 µmol, 15 equiv.) of DMC and add it to the mixture.  crItIcal step The reaction must be performed under basic conditions. After adding all materials, confirm that the reaction pH is >11. If the pH is <11, the conversion rate might decrease and more Et 3 N will be required. 
27|
Collect the fractions containing the products and add 2 mg of NaOH to the combined fractions. ! cautIon The Et 3 N and NaOH are used to stabilize the oxazoline. Make sure that the gel-filtration continues to run at a pH value >10. If the pH is <10, oxazoline may partially decompose during processing.
28|
Lyophilize the fractions to obtain 35 mg of a white solid powder (containing 2 mg of NaOH, yield 91%). ? trouBlesHootInG  pause poInt The oxazoline (22) can be stored at −20 °C for 2 months or it can be frozen at −80 °C for 6 months. 
37|
Incubate at 37 °C for 12 h and monitor the reaction by HPAEC until the terminal GlcNAc is completely hydrolyzed.
38|
Place the reaction mixture into an ice bath.
39|
Add Et 3 N (44 µl, 315 µmol, 45 equiv.) and DMC (17.7 mg, 105 µmol, 15 equiv.) to the tube.  crItIcal step The reaction must be performed under basic conditions. After adding all materials, check whether the reaction has a pH >11. If the pH is <11, the conversion rate might decrease and more Et 3 N will be required.
40|
Incubate in an ice bath for 30 min. Take a 1-µl aliquot for HPAEC analysis (supplementary results) and take a 5-µl aliquot for 1 H NMR detection.  crItIcal step The monitoring is important to ensure a high conversion rate for this reaction. HPAEC could separate the free glycan from the oxazoline through chromatography. 1 H NMR of the oxazoline should indicate a particular proton signal for oxazoline-H 1 at 6.0 p.p.m. as a doublet peak with a coupling constant of ~7.2 Hz. (supplementary results). ? trouBlesHootInG 41| Purify the crude product by solid-phase extraction (SPE) with a PGC cartridge. Flow the sample through the PGC cartridge twice. Wash the cartridge successively with 1 ml of water, 1 ml of 5% MeCN containing 1 mM NaOH, and 1 ml of 10% MeCN containing 1 mM NaOH. Elute the cartridge with 1 ml of 25% MeCN containing 1 mM NaOH.  crItIcal step The NaOH is used to stabilize the oxazoline. Make sure that the SPE continues to run at a pH value >11. If the pH is <11, oxazoline might partially decompose during processing.
42|
Lyophilize the eluent to obtain a white powder (4 mg, 85%). ? trouBlesHootInG  pause poInt The oxazoline (26) can be stored at −20 °C for 2 months or it can be frozen at −80 °C for 6 months. 47| Add 1 µl of 2 mg/ml WT Endo-S (final concentration: 2 µg/ml).  crItIcal step Determine the enzymatic activity of WT Endo-S before the reaction according to the Box 2 protocol. If the Endo-S activity is lower than desired, extend the reaction time or increase the enzyme concentration to complete deglycosylation.
48| Incubate at 37 °C for 2 h. Monitor the reaction with LC-MS and SDS-PAGE until the deglycosylation is complete (supplementary results).
49|
To purify the deglycosylated Herceptin (2a) with an affinity column of protein A beads, first precondition the protein A column (3 ml) with 25 ml of glycine-HCl buffer (100 mM, pH 2.5) and pre-equilibrate with 50 ml of PB (50 mM, pH 8.0).
50| Load the reaction mixture from
Step 47 and flow it through the preconditioned protein A column three times. 54| Elute the column with glycine-HCl (100 mM, pH 2.5, 20 ml), followed by immediate neutralization to a pH value of ~7.5 with glycine-HCl (1 M, pH 8.8).
55|
Combine the IgG fractions and repurify them with the protein A affinity column, repeating Steps 49-54.  crItIcal step Complete removal of WT Endo-S is important. If the purified deglycosylated IgG contains WT Endo-S, the glycoengineered IgG product of the chemoenzymatic transglycosylation will be hydrolyzed by the remaining WT Endo-S in the next step. ? trouBlesHootInG 58| Add 1 µl of 2 mg/ml WT Endo-S (final concentration: 2 µg/ml).
59|
Add 50 µl of 20 mg α-l-fucosidase AlfC (final concentration: 1 mg/ml).  crItIcal step Determine the enzymatic activity of WT Endo-S and AlfC according to the Box 2 protocol before the reaction. If the enzyme activity is lower than desired, extend the reaction time or increase the enzyme concentration to complete deglycosylation. 
66|
Adjust the pH to 7.4 with 0.1 N HCl.  crItIcal step The glycan oxazoline is stabilized with ~6% NaOH after purification. When adding the oxazoline to the antibody solution, the pH increases and adjustment with acid is required. Meanwhile it is also important to avoid overadjustment, as the oxazoline is not stable at low pH. A tip for the pH adjustment in this step is to add a tiny amount (e.g., 1 µl) of HCl multiple times, until the target pH value is reached.
67|
Add 250 µl of 20 mg/ml Herceptin-GlcNAc(Fuc) (2a) (the stock solution from Step 56).
68| Add 6.3 µl of 16 mg/ml Endo-S D233Q, and gently vortex for 5 s.  crItIcal step Determine the enzymatic activity of Endo-S D233Q before the reaction by following the Box 2 protocol. If the enzyme activity is lower than desired, extend the reaction time or increase the enzyme concentration to complete transglycosylation.
69|
Add additional 50 mM, pH 7.4 Tris-HCl buffer until the final volume is 1 ml (final concentrations: IgG: 5 mg/ml; oxazoline: 1mM; D233Q: 0.1 mg/ml).
70|
Incubate the mixture at 30 °C for 2 h and monitor the reaction with SDS-PAGE and LC-MS analysis (see Anticipated Results section; Fig. 8a,b) . ? trouBlesHootInG 71| Immediately purify the product by gel-filtration with a protein-A affinity column by following Steps 49-54.  crItIcal step It is better to purify the sample immediately after the reaction to avoid possible nonenzymatic reactions caused by long reaction times even under low temperature.
72|
Combine the product fractions. Exchange the sample buffer with a 50 mM, pH 7.4 Tris-HCl buffer and concentrate the sample with an Amicon ultracentrifugal filter (30 kDa cutoff). Prepare a stock solution of 5a at a 10 mg/ml concentration in the 50 mM, pH 7.4 Tris-HCl buffer.  pause poInt The 5a stock can be stored at 4 °C for 4 weeks or it can be frozen at −80 °C for 6 months. preparation of 5a by one-pot procedure (Fig. 5) • tIMInG 7 h 74| Weigh 10 mg of SGP non-natural derivative 4a in a 1.5-ml tube.
75|
Follow Steps 17-20 to hydrolyze the azido-glycan from 4a.
76|
Place the solution in an ice bath.
77| Add 11 µl of 500 mg/ml NaOH aqueous solution, 8.8 mg of DMC, and water until the final volume is 100 µl.  crItIcal step For the one-pot chemoenzymatic procedure, we choose NaOH as the base to replace Et 3 N, because in the next step the enzymatic reaction with the Endo-S mutant is more compatible with neutralized sodium salts than triethyl ammonium salts. It is also important to control the pH (should be >11). If the pH is <11, oxazoline formation might be incomplete and it will require more NaOH and DMC to complete the oxazoline formation.
78|
Incubate in an ice bath for 30 min and monitor the reaction with 1 H NMR analysis.  crItIcal step 1 H NMR monitoring on oxazoline formation is important for the one-pot procedure. If incomplete oxazoline formation occurs in this step, enzymatic transglycosylation using this oxazoline in situ might be influenced. 100| Incubate at 37 °C for 1 h. Monitor the reaction by LC-MS to determine the drug-antibody ratio (DAR). Control the DAR value to keep it between 2.5 and 3.5.
101|
Immediately purify the mixture by gel-filtration with a protein-A affinity column according to Steps 49-54.  crItIcal step The purification procedure must be performed immediately once the DAR value is in the desired range. If you do not purify the ADC immediately, the conjugation reaction will keep running and the DAR may increase.
102|
Combine the product fractions and concentrate the sample by centrifugation at 3,200g at 4 °C for 30 min. Prepare a solution of 5 ml of ADC 27 at 1 mg/ml in a 50 mM, pH 7.5 PB containing 10% DMSO. 
108| Lyophilize the compound 28 stock solution from
Step 107 to obtain a white powder (yield >90%). The lyophilized compound 28 powder can be stored at −80 °C for 6 months.
? trouBlesHootInG Troubleshooting advice can be found in table 1. Low purity of SGP (1) Unknown impurities without UV absorbance (2) Terminal sialic acid was partially removed
(1) Purify again with preparative RP-HPLC (2) Control the pH (>7) and temperature (<35 °C) in all procedures. Redo gel-filtration
Box 1,
Step 11
Low yield of SGP (1) Low extraction rate from egg-yolk powder (2) Low elution rate from SPE
(1) In Box 1, step 6, extract with more 40% acetone and monitor with HPLC (2) Elute with more 25% MeCN
Step Herceptin (2a), suggesting successful glycoengineering (Fig. 8a) . LC-MS analysis indicates the deconvolution MS of 5a at 149,890.43, which is in good accordance with the mass increase of the attached azido-glycan. To ensure the correct linkage of the newly attached glycan, 5a was digested with PNGase-F, a commercial enzyme that cleaves the intact N-glycan at the innermost GlcNAc from the Asn297 residue of the glycosites (supplementary results). As shown in the SDS-PAGE gel of Figure 8c , the heavy-chain band of PNGase-F-treated 5a completely shifted to a lower position, suggesting the complete release of N-glycan without any nonenzymatic glycation being observed. Furthermore, LC-MS analysis of the resulting Herceptin-Asp297 (see literature data 26 ) and azido-glycan (Fig. 8d) clearly verifies the enzymatic product that links the N-glycan to the GlcNAc motif of 2a.
The preparation of gsADCs (7a-f) was carried out via the copper-free 'click' reaction 41, 42 with azido-Herceptin (5a or 5b) and DBCO-tagged toxins (6a-d). The increased mass resulting from conjugation of gsADC is confirmed by SDS-PAGE (Fig. 9a) and LC-MS (Fig. 9b) . To validate the site-specific conjugation, 7c was treated with PNGase-F for deglycosylation (supplementary results). Figure 9c shows the heavy-chain bands of 7c at a lower position. This band migrates to the same position as a deglycosylated commercial Herceptin, demonstrating the specific N-glycan conjugation of Herceptin. LC-MS analysis of the released glycan-drug complex (Fig. 9d) displays a series of charged m/z data in close agreement with the calculated molecular weight. These data solidly demonstrate that the glycosite-specific conjugation method can be successfully applied to ADC preparation. 
